US Stock MarketDetailed Quotes

CRBU Caribou Biosciences

Watchlist
  • 1.910
  • -0.030-1.55%
Close Dec 13 16:00 ET
  • 1.840
  • -0.070-3.66%
Post 19:51 ET
172.96MMarket Cap-1.15P/E (TTM)

Caribou Biosciences Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
-91.45%2.02M
-7.75%3.46M
-30.64%2.43M
148.91%34.48M
-3.63%3.56M
616.38%23.66M
-10.42%3.76M
31.46%3.5M
44.31%13.85M
44.28%3.69M
Operating revenue
-91.45%2.02M
-7.75%3.46M
-30.64%2.43M
148.91%34.48M
-3.63%3.56M
616.38%23.66M
-10.42%3.76M
31.46%3.5M
44.31%13.85M
44.28%3.69M
Cost of revenue
Gross profit
Operating expense
5.14%40.26M
28.24%46.97M
39.90%48.43M
25.19%150.54M
19.64%41M
28.33%38.3M
12.26%36.62M
47.20%34.62M
57.03%120.25M
49.23%34.27M
Selling and administrative expenses
1.34%9.84M
13.49%11.49M
64.36%14.64M
1.16%38.46M
13.91%9.72M
-1.40%9.71M
0.76%10.12M
-7.13%8.91M
56.32%38.02M
8.67%8.53M
-General and administrative expense
1.34%9.84M
13.49%11.49M
64.36%14.64M
1.16%38.46M
13.91%9.72M
-1.40%9.71M
0.76%10.12M
-7.13%8.91M
56.32%38.02M
8.67%8.53M
Research and development costs
6.43%30.42M
33.87%35.48M
31.42%33.79M
36.29%112.08M
21.54%31.28M
42.98%28.58M
17.38%26.5M
84.64%25.71M
57.36%82.23M
70.31%25.74M
Operating profit
-161.31%-38.24M
-32.35%-43.5M
-47.84%-46M
-9.08%-116.06M
-22.45%-37.44M
44.86%-14.63M
-15.61%-32.87M
-49.22%-31.12M
-58.85%-106.4M
-49.86%-30.58M
Net non-operating interest income expense
Other net income (expense)
-23.26%3.55M
73.31%5.8M
55.21%4.77M
101.22%14.18M
-14.46%3.13M
4,310.00%4.63M
93.14%3.35M
74.05%3.07M
1,769.50%7.05M
62.84%3.66M
Gain on sale of security
-250.00%-14K
-563.64%-102K
----
95.49%-6K
85.00%-9K
-112.90%-4K
237.50%22K
82.95%-15K
---133K
---60K
Other non- operating income (expenses)
-23.02%3.57M
77.52%5.91M
54.45%4.77M
97.58%14.19M
-15.60%3.14M
3,387.23%4.64M
90.11%3.33M
66.59%3.09M
694.95%7.18M
65.51%3.72M
Income before tax
-246.77%-34.68M
-27.70%-37.7M
-47.03%-41.23M
-2.54%-101.88M
-27.46%-34.31M
62.46%-10M
-10.57%-29.52M
-46.92%-28.04M
-49.17%-99.35M
-48.25%-26.92M
Income tax
175.71%193K
-78.19%70K
Net income
-246.77%-34.68M
-27.70%-37.7M
-47.03%-41.23M
-2.66%-102.07M
-27.85%-34.51M
62.46%-10M
-10.57%-29.52M
-46.92%-28.04M
-48.56%-99.42M
-46.05%-26.99M
Net income continuous Operations
-246.77%-34.68M
-27.70%-37.7M
-47.03%-41.23M
-2.66%-102.07M
-27.85%-34.51M
62.46%-10M
-10.57%-29.52M
-46.92%-28.04M
-48.56%-99.42M
-46.05%-26.99M
Minority interest income
Net income attributable to the parent company
-246.77%-34.68M
-27.70%-37.7M
-47.03%-41.23M
-2.66%-102.07M
-27.85%-34.51M
62.46%-10M
-10.57%-29.52M
-46.92%-28.04M
-48.56%-99.42M
-46.05%-26.99M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-246.77%-34.68M
-27.70%-37.7M
-47.03%-41.23M
-2.66%-102.07M
-27.85%-34.51M
62.46%-10M
-10.57%-29.52M
-46.92%-28.04M
-48.56%-99.42M
-46.05%-26.99M
Basic earnings per share
-216.67%-0.38
12.50%-0.42
0.00%-0.46
15.85%-1.38
9.09%-0.4
72.73%-0.12
-9.09%-0.48
-43.75%-0.46
22.27%-1.64
-41.94%-0.44
Diluted earnings per share
-216.67%-0.38
12.50%-0.42
0.00%-0.46
15.85%-1.38
9.09%-0.4
72.73%-0.12
-9.09%-0.48
-43.75%-0.46
22.27%-1.64
-41.94%-0.44
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue -91.45%2.02M-7.75%3.46M-30.64%2.43M148.91%34.48M-3.63%3.56M616.38%23.66M-10.42%3.76M31.46%3.5M44.31%13.85M44.28%3.69M
Operating revenue -91.45%2.02M-7.75%3.46M-30.64%2.43M148.91%34.48M-3.63%3.56M616.38%23.66M-10.42%3.76M31.46%3.5M44.31%13.85M44.28%3.69M
Cost of revenue
Gross profit
Operating expense 5.14%40.26M28.24%46.97M39.90%48.43M25.19%150.54M19.64%41M28.33%38.3M12.26%36.62M47.20%34.62M57.03%120.25M49.23%34.27M
Selling and administrative expenses 1.34%9.84M13.49%11.49M64.36%14.64M1.16%38.46M13.91%9.72M-1.40%9.71M0.76%10.12M-7.13%8.91M56.32%38.02M8.67%8.53M
-General and administrative expense 1.34%9.84M13.49%11.49M64.36%14.64M1.16%38.46M13.91%9.72M-1.40%9.71M0.76%10.12M-7.13%8.91M56.32%38.02M8.67%8.53M
Research and development costs 6.43%30.42M33.87%35.48M31.42%33.79M36.29%112.08M21.54%31.28M42.98%28.58M17.38%26.5M84.64%25.71M57.36%82.23M70.31%25.74M
Operating profit -161.31%-38.24M-32.35%-43.5M-47.84%-46M-9.08%-116.06M-22.45%-37.44M44.86%-14.63M-15.61%-32.87M-49.22%-31.12M-58.85%-106.4M-49.86%-30.58M
Net non-operating interest income expense
Other net income (expense) -23.26%3.55M73.31%5.8M55.21%4.77M101.22%14.18M-14.46%3.13M4,310.00%4.63M93.14%3.35M74.05%3.07M1,769.50%7.05M62.84%3.66M
Gain on sale of security -250.00%-14K-563.64%-102K----95.49%-6K85.00%-9K-112.90%-4K237.50%22K82.95%-15K---133K---60K
Other non- operating income (expenses) -23.02%3.57M77.52%5.91M54.45%4.77M97.58%14.19M-15.60%3.14M3,387.23%4.64M90.11%3.33M66.59%3.09M694.95%7.18M65.51%3.72M
Income before tax -246.77%-34.68M-27.70%-37.7M-47.03%-41.23M-2.54%-101.88M-27.46%-34.31M62.46%-10M-10.57%-29.52M-46.92%-28.04M-49.17%-99.35M-48.25%-26.92M
Income tax 175.71%193K-78.19%70K
Net income -246.77%-34.68M-27.70%-37.7M-47.03%-41.23M-2.66%-102.07M-27.85%-34.51M62.46%-10M-10.57%-29.52M-46.92%-28.04M-48.56%-99.42M-46.05%-26.99M
Net income continuous Operations -246.77%-34.68M-27.70%-37.7M-47.03%-41.23M-2.66%-102.07M-27.85%-34.51M62.46%-10M-10.57%-29.52M-46.92%-28.04M-48.56%-99.42M-46.05%-26.99M
Minority interest income
Net income attributable to the parent company -246.77%-34.68M-27.70%-37.7M-47.03%-41.23M-2.66%-102.07M-27.85%-34.51M62.46%-10M-10.57%-29.52M-46.92%-28.04M-48.56%-99.42M-46.05%-26.99M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -246.77%-34.68M-27.70%-37.7M-47.03%-41.23M-2.66%-102.07M-27.85%-34.51M62.46%-10M-10.57%-29.52M-46.92%-28.04M-48.56%-99.42M-46.05%-26.99M
Basic earnings per share -216.67%-0.3812.50%-0.420.00%-0.4615.85%-1.389.09%-0.472.73%-0.12-9.09%-0.48-43.75%-0.4622.27%-1.64-41.94%-0.44
Diluted earnings per share -216.67%-0.3812.50%-0.420.00%-0.4615.85%-1.389.09%-0.472.73%-0.12-9.09%-0.48-43.75%-0.4622.27%-1.64-41.94%-0.44
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion with Explanatory Notes--
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Tesla
TSLA
+4.34%
MicroStrategy
MSTR
+4.20%
MARA Holdings
MARA
+0.66%
Apple
AAPL
+0.07%
Microsoft
MSFT
-0.51%

Unlock the Full List

Investment Theme Gene Editing
Gene Editing
Intraday-0.48%